Novotech

Press Releases

Allergan Announces FDA Acceptance of NDA Filing for Oxymetazoline HCI Cream 1.0%

Allergan plc announced that the New Drug Application (NDA) filing for oxymetazoline HCl cream 1.0%, an investigational topical prescription product for the treatment of persistent facial erythema (redness) associated with rosacea in adults, has been accepted by the U.S....

Seqirus receives FDA approval for FLUCELVAX QUADRIVALENT

CSL announced that the US FDA has approved Seqirusโ€™ FLUCELVAX QUADRIVALENTโ„ข (Influenza Vaccine), the first four-strain, cell culture-derived, inactivated seasonal influenza vaccine for people aged four years and older. FLUCELVAX QUADRIVALENT helps protect against the two...

Rituximab regulatory submission accepted by European Medicines

Sandoz advances biosimilar portfolio with sixth major biosimilar file acceptance in less than one year Sandoz is seeking approval for all indications included in the reference product's label. Sandoz' submission includes data from multiple clinical trials...

FDA Expands Invokamet Label to Include First-Line Treatment of with type 2 diabetes

Janssen Pharmaceuticals, Inc announced the U.S. FDA has approved INVOKAMETยฎ, a fixed-dose combination therapy of INVOKANAยฎ (canagliflozin) and metformin hydrochloride, for first-line treatment of adults with type 2 diabetes. With this new approval, INVOKAMETยฎ may now...

Bayer Comments on Monsantoโ€™s Statement Regarding Proposed Transaction

Bayer announced that it looks forward to engaging in constructive discussions with Monsanto regarding the proposed transaction. Bayer reiterated that its USD 122 per share all-cash proposal provides full and certain value for Monsanto shareholders. โ€œWe...

Novo Nordisk IDegLira receives positive 16-0 vote in favour of approval from FDA

Novo Nordisk announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) voted 16-0, recommending the approval of IDegLira for the treatment of adults with type 2 diabetes. IDegLira is a...

Anti-Cancer Agent vastin ,Obtained Approval for Additional Indication of Advanced or Recurrent Cervical Cancer

Chugai Pharmaceutical Co Ltd announced that it gained approval by the Japanese Ministry of Health, Labour and Welfare (MHLW) on May 23, 2016, for โ€œadvanced or recurrent cervical cancer,โ€ as new additional indication for the anti-cancer agent / anti-VEGF...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป